UHealth - University of Miami Health System

E-mail a Friend

Nicolas Acquavella Pesantes, M.D.

General Information

Nicolas  Acquavella Pesantes, M.D.



  • Internal Medicine
  • Hematology/Oncology - Internal Medicine


English, Italian, Spanish

Clinical Areas

Melanoma; Immunotherapy

Video Introduction


  • American Board of Internal Med-Medical Oncology
  • American Board of Internal Medicine


  • Assistant Professor of Clinical Medicine
  • Member, Immunotherapy Program
  • Member, Melanoma Program
  • Member, Phase I Clinical Trials Program

Research Interests

Clinical Trials:
1. A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAF V600 Mutant Melanoma.

2. A Phase III Randomized trial comparing High Dose Interferon to MK-3475 (Pembrolizumab) in patients with high risk resected Melanoma.

3. Phase 1b Trial of AEB071, a PKC Inhibitor, in Combination with BYL719, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma.

4. A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for the Treatment of Unresectable Stage IIIB to IVM1c Melanoma.

5. A phase 1b study of intratumoral CAVATAK (Coxsackievirus A21) and ipilimumab in patients with advanced melanoma.

6. Proof of concept study of vorinostat, a histone deacetylase inhibitor, in patients with class 2 high risk uveal melanoma.

7. A phase 1 Open-label, Multi-center study of the Safety and Efficacy of IMCgp100 using the Intrapatient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma (Opening soon)






MD, Universidad Central de Venezuela

Residency, Yale New Haven Hospitals

Fellowship, National Cancer Institute / National Institutes of Health


Nicolas Acquavella, M.D., is a board-certified medical oncologist dedicated to providing innovative and advanced treatment options to patients with metastatic melanoma and pancreatic cancer. Dr. Acquavella’s research focuses on mobilizing the body’s immune system to seek out and destroy cancer cells. In close collaboration with a multidisciplinary group of scientists, pharmaceutical companies and clinicians Dr. Acquavella works to move the most promising cancer therapies from the laboratory into the clinic. In collaboration with his colleagues at the Bascom Palmer Eye Institute at the University of Miami – the No. 1 eye hospital in the nation – Dr. Acquavella is committed to develop novel therapies for uveal melanoma, a rare type of melanoma that occurs in the eye and for which no effective therapies exist. His current research involves combining immune-based therapies with viruses genetically modified to destroy cancer cells.

E-mail a Friend